A Study of Effectiveness of Alfuzosin in Benign Prostatic Hyperplasia Patients During Prostate Awareness Campaign in Year 2006-2009 in Hospital Universiti Sains Malaysia (HUSM)
Benign prostate hyperplasia is a common benign disease in men after age of 50. Its prevalence is about 19 to 30 %. It is not a life threatening disease, but it does significantly reduce the quality of life in both men as well as their opposite partner. This condition affects the men in their dail...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/60773/1/DR%20GOH%20CHENG%20HOOD%20-%20e.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Benign prostate hyperplasia is a common benign disease in men after age of 50.
Its prevalence is about 19 to 30 %. It is not a life threatening disease, but it does
significantly reduce the quality of life in both men as well as their opposite partner. This
condition affects the men in their daily routine activities, as well as their sexual lifestyle.
The symptoms bothering the patients and disturbing their sleep are termed as Lower Urinary Tract Symptom (LUTS). These symptoms are recorded by using an objective
scoring system, International Prostate Symptoms Score (IPSS) which was validated by
World Health Organization (WHO). It contains seven questions and with scores of 0 to
5 for each question. Sum of all the scores will determine how severe the LUTS is.
Although it is a bothersome disease, it is also a treatable disease. It can be treated either
medically or surgically. The aim of this study is to find out how effective is the
medication- Alfuzosin (Xatral) in this disease. It is a cross sectional study, the patients diagnosed as BPH from year 2006 to
2009 were recruited. A total of 307 who fulfilled the inclusion and exclusion criteria
were included in the study. Patients who were recruited will be contacted by phone and
appointment will be given, new set of IPSS and uroflow rate (Qmax) will be obtained
and recorded during the interview. The data will be compared with the data prior to
initiation of treatment and the result will be analyzed using SPSS version 19. The medical treatment outcome using Alfuzosin was compared with pre and
post treatment using IPSS, Qmax. The data was analyzed using two means paired t-test
and the results are significantly different in the two test groups. The means of IPSS
improved significantly from 15.55 to 5.53 (p<0.001) and means Qmax from 11.74 to
14.51 (p <0.001). In the study group, 2% of the study population presented with acute urinary retention, which was resolved after starting on Alfuzosin; no others study
patients presented with acute urinary retention during the period of study. The result
also showed that serum prostate specific antigen levels decreased in patients on medical
treatment from 4.69ng/ml to 3.33ng/ml (p=<0.001). v |
|---|